Research Analysts’ Weekly Ratings Changes for Arrowhead Pharmaceuticals (ARWR)

Arrowhead Pharmaceuticals (NASDAQ: ARWR) recently received a number of ratings updates from brokerages and research firms:

• 5/13/2026 – Arrowhead Pharmaceuticals had its price target raised by Sanford C. Bernstein from $35.00 to $46.00. They now have a “market perform” rating on the stock.
• 5/8/2026 – Arrowhead Pharmaceuticals had its price target raised by Royal Bank Of Canada from $80.00 to $87.00. They now have an “outperform” rating on the stock.
• 5/6/2026 – Arrowhead Pharmaceuticals had its “hold (c-)” rating reaffirmed by Weiss Ratings.
• 5/1/2026 – Arrowhead Pharmaceuticals is now covered by JPMorgan Chase & Co.. They set an “overweight” rating and a $88.00 price target on the stock.
• 4/21/2026 – Arrowhead Pharmaceuticals was upgraded by Morgan Stanley from “equal weight” to “overweight”. They now have a $100.00 price target on the stock, up from $78.00.
• 3/25/2026 – Arrowhead Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $100.00 price target on the stock.

Insider Buying and Selling

In related news, insider James C. Hamilton sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $64.19, for a total transaction of $641,900.00. Following the transaction, the insider directly owned 236,958 shares of the company’s stock, valued at approximately $15,210,334.02. The trade was a 4.05% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Hongbo Lu sold 2,970 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $76.88, for a total value of $228,333.60. Following the transaction, the director directly owned 52,012 shares in the company, valued at $3,998,682.56. This trade represents a 5.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 36,065 shares of company stock valued at $2,554,562. Corporate insiders own 3.60% of the company’s stock.

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.